AItrix Secures Series B Funding... 27.1 Billion KRW Raised

Medical artificial intelligence (AI) company AItrics announced on the 21st that it has successfully raised a total of 27.1 billion KRW in Series B funding from nine domestic and international venture capital (VC) firms.

Kim Kwang-jun, CEO of AItrics [Photo by AItrics]

In this Series B round, existing investors Premier Partners, BNH Investment, and BSK Investment continued their follow-up investments, while Boneum Investment, DS Investment & Securities, Almus Investment, HB Investment, Shin Young Securities, and HRZ participated as new investors. Including the 7.5 billion KRW raised through the 2017 seed round and 2019 Series A, and the 3.5 billion KRW secured in the 2021 pre-Series B, the cumulative investment amount reaches 38.1 billion KRW.

Founded in 2016, AItrics is a specialized medical AI company based on biosignals that developed AItrics-VC (Vital Care), an AI solution for predicting patient condition deterioration. Vital Care is a medical AI software that monitors the condition of hospitalized patients in real-time to predict early deterioration such as sepsis, death, and cardiac arrest. Vital Care analyzes a total of 19 comprehensive data points, including six vital signs, 11 blood test results, and patient consciousness level and age, derived from electronic medical records (EMR), enabling more accurate early detection of abnormal signs in patients.

Since receiving approval from the Ministry of Food and Drug Safety in October 2022, Vital Care has been used as a non-reimbursed service under the Ministry of Health and Welfare’s new medical technology evaluation exemption system. It has been introduced in over 40 hospitals, including Gangnam Severance Hospital and Korea University Anam and Guro Hospitals, generating sales.

AItrics plans to use the funds raised this time to advance technology, develop new products, and obtain approval from the U.S. Food and Drug Administration (FDA). In particular, having attracted investment from global investors in this Series B round, the company explained that it has laid the groundwork for full-scale overseas expansion.

Kim Kwang-jun, CEO of AItrics, said, “We express our gratitude to the investors who recognized AItrics’ achievements and future value. Through this investment, we will strengthen medical AI research by expanding specialized personnel in each field and pioneer new pipelines to seek continuous growth of the company.” He added, “We will strive for global expansion beyond Korea so that our technology can benefit more medical professionals and patients.”

Yoon Ha-young, Managing Director of Premier Partners, who decided to make a follow-up investment this time as well, explained, “Amid the remarkable global growth of medical AI recently, we have focused on AItrics’ outstanding research personnel and excellent biosignal technology since the Series A stage. We judged that Vital Care, which predicts severe diseases and death, can bring positive changes to the medical market environment, leading us to make an additional investment.”

This content was produced with the assistance of AI translation services.